The company has shed its former “GenEdit” name and strategy in favor of a plan to develop its own medicines, starting with a ...

The potentially $2.1 billion collaboration gives Novo access to technologies that are meant to help optimize the delivery of ...

One of biotech’s longest-tenured leaders, Pops steered Alkermes through several reinventions, the latest of which has made it ...

The lawsuit seeks to reverse the abrupt overhaul of the U.S. immunization schedule as well as the federal government’s allegedly “unlawful” reformation of a key vaccine panel.

According to one analyst, the alliance and early data “validate” the oncology work of Vir, which was once purely an ...

Novo’s answer to a closely watched Lilly drug spurred roughly 20% weight loss after 24 weeks in a Phase 2 trial, results one of its executives claimed to be “differentiating.” ...

The deal hands GSK a drug it views as a potentially “best-in-class” therapy for blood pressure diseases like pulmonary arterial hypertension — the target of Merck’s fast-selling Winrevair.

Wegovy and Ozempic’s list prices will be reduced by as much as 50% effective next year. Elsewhere, Palvella’s market value surged past $1 billion while Pfizer nabbed rights to another obesity drug.

Investors were looking for a greater difference between Ocular’s experimental medicine and a low-dose version of Eylea, ...

The new duties will go into effect Feb. 24, although the president has since signaled he will raise the rate to 15%.

Another FDA knockback for a gene therapy has investors and analysts redrawing expectations for the rare disease drug developer.

Lyell’s trial will test its experimental cancer cell therapy directly against marketed counterparts. Elsewhere, Biogen swapped board chairs and venture firms are joining up at a “pivotal time” for ...